Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTU-MultiHIV B-clade + MVA HIV-B
- Development stage
- Unknown
- Lead developer
- FIT Biotech
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GTU-MultiHIV B-clade + MVA HIV-B is a combination therapeutic vaccine regimen designed as a prime-boost strategy for the treatment of HIV-1 infection. The regimen consists of a DNA vaccine prime (GTU-MultiHIV B-clade) and a Modified Vaccinia Ankara (MVA) viral vector boost (MVA HIV-B). The GTU-MultiHIV B-clade component, developed by FIT Biotech, utilizes a non-replicating expression vector to deliver a synthetic fusion protein comprising multiple HIV-1 antigens (Rev, Nef, Tat, p17/p24, and various CTL epitopes). The MVA HIV-B component expresses Gag, Pol, and Nef proteins from the HIV-1 LAI strain. This strategy aims to induce robust cellular immune responses to control viral replication and is being investigated as a potential functional cure approach, particularly for maintaining viral suppression after antiretroviral therapy (ART) interruption.
- Other names
- GTU-MultiHIV B clade vaccine + MVA-B
02
Targets
Env (HIV-1 envelope glycoprotein)PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptaseGag (HIV-1 Gag polyprotein)Tat (HIV-1 Tat)Nef (HIV-1 Nef)Rev (HIV-1 Rev)
Beyond the preview
Go deeper on GTU-MultiHIV B-clade + MVA HIV-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTU-MultiHIV B-clade + MVA HIV-B.